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Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disturbances in women of reproductive age. Besides
its well-known eﬀects on reproductive health, it is also linked to increased cardiovascular risk in later life. The aim of this study is
to investigate some classical cardiovascular risk factors in a crossectional study of Bulgarian women with PCOS and/or obesity. We
performedaretrospectivemedicalchartreviewof375womenfromanuniversityendocrineclinic.Wefoundsigniﬁcantdiﬀerences
in the indices of carbohydrate metabolism, blood pressure, lipid proﬁle, rate of liver steatosis, and the levels liver enzymes and
hematological results between the lean and obese PCOS women. Obese women without PCOS did not show signiﬁcantly diﬀerent
results in their OGGT form obese PCOS women. Waist-to-stature-ratio (WSR) correlated better with the baseline IRI levels and
lipid proﬁle than waist-to-hip-ratio (WHR) that makes it a better marker for unfavorable metabolic proﬁle.
1.Introduction
PCOS is a prevalent disorder that aﬀects approximately 6–
10% of women of reproductive age [1, 2] and is a major
cause of menstrual disturbances, hirsutism, and female
anovulatoryinfertility.ManyPCOSwomenshowevidenceof
insulin resistance and hyperandrogenism. Current evidence
suggeststhatinsulinresistanceandcompensatoryhyperinsu-
linemia are a central feature of PCOS [3]. Hyperinsulinemia
appears to play an important pathogenic role in the hyper-
androgenism of both obese and lean women with PCOS
[4–6]. According to some studies, PCOS patients have an
increased risk for diabetes mellitus [7, 8]a n do f t e ns h o wa n
adverse cardiovascular risk proﬁle-increased rate of arterial
hypertension [9, 10], dislipidemia [10–14], and subclinical
inﬂammation and atherosclerosis [15–17]. Cardiovascular
risk factors are usually present even in younger age and
this suggests that the chronic disturbances in hormonal
and metabolic status typical for the syndrome predispose
the patients to development of early atherosclerosis and
premature clinical presentation of cardiovascular disease.
Obesity plays an important role in the pathogenesis
of PCOS, and around 30–75% of PCOS women are obese
[18–20]. Over the last 20 years, the prevalence of obesity has
dramatically increased, with probable associated increase
in PCOS. Obesity contributes to the prevalence of the
metabolic syndrome in PCOS patients [21]. Central obesity
is often associated with PCOS [22] and carries increased risk
for developing cardiovascular disease and type 2 diabetes
[23]. The speciﬁc indicators of abdominal obesity are
better for discriminating the high coronary risk than the
usual obesity indicator BMI (body mass index) [24]. In
clinical practice waist-to-hip ratio (WHR) has been used to
determine the presence of central obesity. There are some
indications however that waist-to-stature ratio (WSR) or
waist circumference may predict cardiovascular risk better
than BMI or WHR [25]. WSR has not been thoroughly
studied as a predictor of cardiovascular risk in patients
with PCOS. The aim of this study is to investigate some
classical cardiovascular risk factors in a crossectional study
of Bulgarian women with PCOS and/or obesity.
2.MaterialsandMethods
The sources of information in this study were the available
medical charts of the patients referred to the Clinic of2 Obstetrics and Gynecology International
Endocrinology in Alexandrovska University Hospital-Soﬁa
for the last 21 years (starting year 1990). In this retrospective
study were included patients with diagnosed PCOS or
obesity that had suﬃcient data in their medical charts to be
included in the analysis.
Electronic database was created that included the follow-
ing information for each patient.
(1) General Information: name, age, place of residence,
date of admittance, hospital stay.
(2) Anthropometric Data: height, weight, body mass in-
dex (BMI), waist circumference, hip circumference,
waist-to-hip ratio (WHR), waist-to-stature ratio
(WSR).
(3) Obesity was accepted at BMI ≥ 30kg/m2.
(4) Polycystic Ovary Syndrome was diagnosed according
to the ESHRE-ASRM criteria—two out of the follow-
ing:(1)oligo/amenorrhea;(2)clinicalorbiochemical
hyperandrogenism; (3) polycystic ovaries at ultra-
sound examination when all other endocrine causes
are excluded.
(5) Arterial Hypertension w a sa c c e p t e di ft h e r ew a ss u c ha
diagnosisintheﬁleand/ortherewasantihypertensive
treatment and/or measured during the hospital stay
arterial blood pressure ≥140/90mmHg. The dura-
tion of the hypertension, present blood pressure—
systolic (SBP) and diastolic (DBP) number and type
of antihypertensive medications were also recorded
(6) Lipid Proﬁle: total cholesterol (TC), HDL-cholesterol
(HDL), LDL-cholesterol (LDL), VLDL-cholesterol,
triglycerides (TG). Dislipidemia was accepted if there
was such a diagnosis in the ﬁle and/or there was any
treatment for dislipidemia and/or measured during
the hospital stay TC > 5.2mmol/L, and/or HDL <
1.3mmol/L and/or TG > 1.8mmol/L. The duration
ofthedislipidemia,presentlipidproﬁle,typeoftreat-
ment and number of medications were also recorded.
(7) Gynecological History: number of pregnancies and
births, miscarriages, ageof menarche, duration of the
menstrual cycle, menstrual disturbances (amenor-
rhea, oligomenorrhea, hypermenorrhea, polymenor-
rhea, opsomenorrhea). Regular menstrual cycle was
deﬁned as a menstrual cycle between 21 and 35 days
and with intercycle variability 2-3 days. Oligomen-
orrhea was deﬁned as a menstrual cycle longer than
35 days and shorter than 6 months. Amenorrhea was
deﬁned as a menstrual cycle longer than 6 months.
(8) Data about the presence of Clinical Hyperandro-
genism (hirsutism, acne, androgenic alopecia).
(9) Results form the Oral glucose Tolerance Test (OGTT):
blood glucose and imunoreactive insulin (IRI) on 0,
60, and 120min.
(10) Hormonal Status (testosterone, androstendione, de-
hydroepiandrosteron sulphate (DHEAS), 17-OH-
progesterone, estradiol, LH, FSH, TSH, cortisol
rhythm, prolactin, etc.).
(11) Liver Enzymes: ASAT, ALAT, GGT, AP
(12) Hematological Status (after exclusion of actual acute
inﬂammation): hemoglobin, hematocrit, red blood
cells (RBC), white blood cells (WBC), mean cor-
puscular volume (MCV), mean corpuscular hemo-
globin (MCH), mean corpuscular hemoglobin con-
centration (MCHC), mean platelet volume (MPV),
erythrocyte sedimentation rate (ESR).
(13) UltrasoundDataforliversteatosis(fattyliverdisease).
(14) Gynecological Ultrasound Data:r i g h ta n dl e f to v a r y
measurements and volume, presence of polycystic
ovaries, size of the uterus, endometrium.
(15) ECG Results: heart rate, QT-interval, RR-interval,
presence of ischemia.
(16) Data about Medication Use: metformin or combined
oral contraceptives (COC)—type and dose.
(17) Data about Ovarian Surgery: wedge resection or en-
doscopic ovarian drilling.
All laboratory tests were performed in the Central Clinical
Laboratory of the Alexandrovska University Hospital in So-
ﬁa, which is the reference laboratory for the country. Because
in the diﬀerent periods included in the retrospective study
there were some diﬀerences in the reﬀerence ranges, we used
the following formula to unify the data:
Y = a0 +
Δa(x −b0)
Δb
,( 1 )
where Y is the standard value; a0 is the lower limit of the
standard reference range, b0 is the lower limit of the given
scale, Δa is the diﬀerence between the upper and the lower
limit of the standard reference range.
Hormones from the gonadal axis were measured during
the early follicular phase after spontaneous or progestin in-
duced bleeding.
For standard reference range of the hormones were ac-
cepted the following:
Testosterone—0.3–3.0nmol/L,
Androstendione—0.73–10.7nmol/L,
17-OH-progesterone—0.45–3.3nmol/L,
DHEAS—1.65–11 mcmol/L,
Estradiol—0.08–0.79pmol/L,
LH—0.7–9.0mU/L,
FSH—0.6–9.5mU/L,
Prolactin—50–659mU/L,
Cortisol 8 o’clock—171–536nmol/L,
Cortisol 22 o’clock—64–340nmol/L,
TSH—0.2–4.2mU/L.
In the study, were included premenopuasal women with
obesity and/or PCOS. Exclusion criteria were considered as
age less than 18 or higher than 45 years, postmenopausal
state, severe hepatic, cardiovascular or endocrine disorders
(incl. diabetes), or other concurrent medical illnesses. The
patients were divided into three groups—group 1 Obese;
group 2 Lean PCOS, and group 3 Obese PCOS. Comparison
was made between the data from these three groups.Obstetrics and Gynecology International 3
Table 1: Anthropometric characteristics of the groups.
Group 1
Obese
(n = 125)
Group 2
Lean PCOS
(n = 94)
Group 3
Obese PCOS
(n = 82)
Age (years) 26.50 ±5.47 25.17 ±4.64 26.26 ±5.64
Height (cm) 162.99 ±6.09 163.39 ±6.52 163.68 ±6.70
Weight (kg) 99.82 ±17.00
∧∧∧ 61.56 ±10.32
∗∗∗ 97.09 ±14.07
BMI (kg/m2)3 7 .55 ±5.95
∧∧∧ 23.04 ±3.47
∗∗∗ 36.21 ±4.58
Waist (cm) 106.92±12.49
∧∧∧ 77.81 ±9.87
∗∗∗ 103.69 ±10.24
Hip (cm) 121.78±11.70
∧∧∧ 96.93 ±8.34
∗∗∗ 118.92 ±9.39
WHR 0.86 ±0.08
∧∧∧ 0.79 ±0.06
∗∗∗ 0.87 ±0.08
WSR 0.65 ±0.08
∧∧∧ 0.47 ±0.06
∗∗∗ 0.63 ±0.07
∗∗∗P<0.001 between group 2 and group 3.
∧∧∧P<0.001 between group 1 and group 2.
Table 2:Comparisonbetweentheresultsfromoralglucosetolerancetest,lipidproﬁle,bloodpressuremeasurement,andECGcharacteristics
between the three groups.
Group 1 Group 2 Group 3
Obese Lean PCOS Obese PCOS
nn n
Fasting blood glucose (mmol/L) 125 4.37 ±1.02 94 4.25 ±0.75
∗ 82 4.63 ±0.94
Blood glucose on 60min of OGTT (mmol/L) 110 7.62 ±1.99
∧ 75 6.72 ±2.08
∗∗ 78 7.87 ±2.09
Blood glucose on 120min of OGTT (mmol/L) 119 5.86 ±1.62 74 5.70 ±1.45 81 6.06 ±1.54
Fasting IRI (mU/L) 86 18.24 ±9.86
∧∧∧ 72 8.16 ±4.22
∗∗∗ 69 20.35 ±11.67
IRI on 60min of OGTT (mU/L) 54 108.70 ±78.26
∧∧ 62 65.50 ±49.05
∗∗∗ 54 129.26 ±79.32
IRI on 120min of OGTT (mU/L) 57 66.69 ±50.11
∧ 61 39.40 ±33.11
∗∗∗ 53 90.22 ±74.22
HOMA index 86 3.80 ±2.41
∧∧∧ 72 1.56 ±0.97
∗∗∗ 68 4.32 ±2.69
Fasting glucose/insulin ratio 86 0.34 ±0.22
∧∧∧ 72 0.68 ±0.39
∗∗∗ 68 0.32 ±0.22
Dislipidemia (%) 125 44.0%∧∧∧ 91 15.4%∗∗∗ 81 40.7%
Treatment for dislipidemia (%) 125 4.8% 91 1.1% 80 2.5%
Total cholesterol (mmol/L) 122 4.73 ±0.94 89 4.60 ±0.97 81 4.68 ±0.81
HDL cholesterol (mmol/L) 95 1.27 ±0.28
∧∧∧ 52 1.52 ±0.40
∗∗ 66 1.28 ±0.34
LDL cholesterol (mmol/L) 95 2.73 ±0.88 52 2.78 ±0.94 65 2.64 ±0.73
VLDL cholesterol (mmol/L) 94 0.67 ±0.43
∧∧∧ 49 0.37 ±0.18
∗∗∗ 64 0.71 ±0.43
Triglycerides (mmol/L) 125 1.76 ±0.75
∧∧∧ 89 0.91 ±0.37
∗∗∗ 80 1.56 ±0.72
Arterial hypertension (%) 125 31.2%∧∧∧ 93 1.1%∗∗∗ 81 29.6%
Treatment for arterial hypertention (%) 125 12.8%∧∧ 93 1.1%∗∗∗ 81 18.5%
Systolic blood pressure (mmHg) 125 124.00 ±12.44
∧∧∧ 90 113.78±12.09
∗∗∗ 81 123.77 ±14.41
Diastolic blood pressure (mmHg) 125 80.00 ±9.20
∧∧∧ 90 73.11 ±8.16
∗∗∗ 81 80.06 ±10.29
cQT-interval (sec) 19 0.41 ±0.02 9 0.41 ±0.04 18 0.40 ±0.03
RR-interval (sec) 22 0.73 ±0.13
∧∧ 90 .89 ±0.16
∗ 19 0.74 ±0.09
Heart rate (bpm) 27 84.48 ±11.46
∧∧∧ 96 8 .22 ±9.64
∗ 25 79.48 ±8.95
∗P<0.05; ∗∗P<0.01; ∗∗∗P<0.001 between group 2 and group 3.
∧P<0.05; ∧∧P<0.01; ∧∧∧P<0.001 between group 1 and group 2.
n = number of patients.
As a part of this retrospective study, we performed an
analysis of the data from the OGTT using diﬀerent criteria
for insulin resistance:
(1) elevated baseline IRI,
(2) decreased baseline glucose/insulin ratio (less than
0.333mmol/L/mU/L),
(3) increase of the level of the IRI more than 100mU/L
during the OGTT,
(4) increaseoftheleveloftheIRImorethan5timesfrom
the baseline,
(5) HOMA index more than 2.0, calculated as baseline
blood glucose (mmol/L) multiplied by baseline IRI
(mU/L) and then devided by 22.5.4 Obstetrics and Gynecology International
Table 3: Comparison between liver enzymes and the rate of liver steatosis and the blood count between the three groups.
Group 1 Group 2 Group 3
Obese Lean PCOS Obese PCOS
nn n
ASAT (U/l) 100 20.08 ±10.57 57 20.37 ±21.10 66 25.27 ±19.15
ALAT (U/l) 107 23.76 ±16.33
∧∧ 61 17.57 ±9.65
∗∗ 71 28.07 ±23.68
AP (U/l) 105 109.20 ±46.102 54 90.85 ± 49.74
∗∗ 62 120.58 ±
55.07
GGT (U/l) 101 24.11 ±14.33
∧ 56 16.97±11.62
∗∗∗ 71 30.30 ±21.90
Steatosis (%) 35 57.1%∧∧ 13 7.7%∗∗∗ 25 72.0%
RBC 125 4.59 ±0.49 89 4.51 ±0.37 79 4.66 ±0.39
Hemoglobin 125 135.58 ±12.45 89 135.66 ±12.40 80 139.80±9.66#
Hematocrite 104 0.40 ±0.04 86 0.40 ±0.03 74 0.41 ±0.03
MCV 88 86.05 ±7.12
∧∧∧ 67 90.26 ±4.96 56 87.77 ±5.09
MCH 87 29.04 ±2.78
∧∧∧ 67 30.48 ±1.66 56 29.66 ±1.71
MCHC 82 334.87 ±17.14 63 336.83 ±13.95 49 334.82±19.79
Platelets 106 306.96 ±82.36
∧∧ 81 272.69 ±57.37 74 307.32±67.85
MPV 78 8.58 ±1.13 59 8.71 ±0.98 46 8.73 ±1.09
WBC 123 7.87 ±2.51
∧∧ 87 6.88 ±2.14
∗ 80 7.84 ±2.24
ESR 124 15.11 ±9.16
∧∧∧ 83 7.75 ±5.51
∗∗∗ 78 14.38 ±10.04
#P<0.05; between group 1and group 3.
∗P<0.05; ∗∗P<0.01; ∗∗∗P<0.001 between group 2 and group 3.
∧P<0.05; ∧∧P<0.01; ∧∧∧P<0.001 between group 1 and group 2.
n = number of patients.
For this part of the study were used only the patients that
had the full data from the OGTT (blood glucose on 0,60 and
120min and IRI on 0, 60, and 120min). For every patient
were examined the presence of insulin resistance by each of
these criteria and its prevalence in the general group and
separately in each subgroup.
2.1. Statistical Methods. The data were processed using the
statistical package SPSS 16.0. The level of signiﬁcance for
rejecting the null hypothesis was P<0.05. The following
statistical methods were applied: descriptive analysis, varia-
tion analysis, Kolmogorov-Smirnov’s one sample nonpara-
metric test, Student’s t-test for two independent samples,
Kruskal-Wallis’ nonparametric test for several independent
samples, Mann-Whitney’s nonparametric test for two inde-
pendent samples, one-way analysis of variance between-
groups ANOVA with post hoc tests, and correlation analysis.
3. Results
Initially the present study included 375 women. After age-
matching of the three groups, 74 women with obesity
w e r ee x c l u d e da n da tt h ee n d3 0 1w o m e na g e d1 8t o4 0
years participated in the analysis. Patients’ characteristics are
shown in Table 1.
Obese PCOS women did not signiﬁcantly diﬀer in
weight,BMI,waist,hip, WHR, orWSRfromtheobesewom-
en without PCOS.
The results from the comparison between the three
groups are shown on Tables 2–7. A statically signiﬁcant
diﬀerence was found regarding the results from the OGTT
(blood glucose on 0 and 60min and IRI on 0, 60, and
120min), HOMA-index, glucose/insulin ratio, the rate of
hypertension and dislipidemia, systolic and diastolic blood
pressure, HDL, VLDL, and TG (Table 2), the rate of liver
steatosis and the levels of ALAT, GGT, and AP, and hema-
tological results (WBC and ESR) (Table 3) between the lean
and obese PCOS women.
Obese women without PCOS did not show signiﬁcantly
diﬀerent results in their OGTT form obese PCOS women.
These two groups however diﬀer in the levels of testosterone
and LH, ovarian volume (Table 4) and the rate of hirsutism
(Table 6) and menstrual disturbances (length of menstrual
cycle and the prevalence of oligomenorrhea).
Astrongpositivecorrelationwasfoundbetweenthebody
weight and baseline IRI and HOMA index in general (r =
0.58 and r = 0.59, resp., P<0.01) that is most prominent in
leanPCOSgroup.ThecorrelationisweakerforIRIon60and
120min of OGTT (r = 0.25 and r = 0.14, resp., P<0.01).
It is worth mentioning that WSR correlates better with the
baseline IRI levels and HOMA-index (r = 0.31 and r = 0.59,
resp., P<0.05) than WHR (r = 0.18 and r = 0.38, resp., P<
0.05) that makes it a better marker for unfavorable metabolic
proﬁle.
A weak but statistically signiﬁcant correlation was ob-
served in the total group between the results from the OGTT
(except fasting blood glucose) and systolic and diastolic
blood pressure that disappear when patients are divided into
groups according to diagnosis, except for the intermediate
correlation that exists between SBP, DBP, and blood glucose
on 120min (r = 0.263 and r = 0.224, P<0.05) IRI onObstetrics and Gynecology International 5
Table 4: Comparison of hormone levels and the indices of ovarian function between the three groups.
Group 1 Group 2 Group 3
Obese Lean PCOS Obese PCOS
nn n
Testosterone (nmol/L) 53 2.03 ±1.22 85 2.42 ±1.51 67 2.94 ±1.72##
Estradiol (pmol/L) 37 0.39 ±0.34 62 0.45 ±0.47 40 0.72 ± 1.50
Androstendione (nmol/L) 17 11.58 ±9.32 48 13.16 ±9.33 33 13.34 ±7.53
DHEAS (mcmol/L) 24 7.32 ±4.29 60 9.24 ±4.76 54 9.49 ± 4.98
17-OH-progesteron (nmol/L) 16 2.50 ±1.45 37 3.40 ±2.93 38 3.49 ± 2.76
LH (U/L) 42 2.91 ±1.85
∧∧∧ 74 5.74 ±4.01 59 5.17 ±4.25##
FSH (U/L) 42 3.33 ±1.94 76 3.40 ±2.07 60 3.25 ± 1.81
Prolactin (U/L) 47 355.19 ±235.88 54 388.45 ±241.52 49 310.65±184.77
Cortisol 8:00 o’clock (nmol/L) 52 405.14 ±119.38 30 414.67 ±156.03 41 392.35±134.26
Cortisol 22:00 o’clock (nmol/L) 44 103.35 ±97.67 15 111.37 ±39.19 29 138.44±113.19
TSH (U/L) 62 2.09 ±0.99 39 2.02 ±1.51 45 1.84 ± 1.17
Presence of polycystic ovaries (PCO) (%) 31 16.1%∧∧∧ 85 84.7% 62 79.0%###
Right ovary PCO (%) 29 17.2%∧∧∧ 74 87.8% 56 67.9%
###
Left ovary PCO (%) 29 13.8%∧∧∧ 77 74.0% 56 75.0%###
Right ovary volume (mL) 18 6.99 ±3.36
∧∧ 54 11.75 ±6.16 37 10.37 ±5.94
Left ovary volume (mL) 20 4.87 ±3.06
∧∧ 54 9.18 ±4.46
∗∗∗ 35 11.13 ±6.16
Age of menarche (years) 87 12.73 ±1.66 86 13.05 ±1.74 69 12.66 ±1.62
Length of menstrual cycle (days) 44 29.55 ±6.01
∧∧∧ 56 51.14 ±23.12
∗ 30 40.87 ±16.86##
Duration of menstrual bleeding (days) 33 4.88 ±2.84 44 4.95 ±1.09 22 6.27 ± 5.55
Rate of menstrual disturbances (%) 107 39.3%∧∧∧ 92 78.3% 79 81.0%###
Regular menstrual cycle (%) 106 65.1%∧∧∧ 93 23.7% 80 20.0%###
Oligiomenorrhea (%) 104 28.8%∧∧∧ 93 66.7% 80 66.2%###
Hypermenorrhea (%) 103 6.8% 91 3.3% 80 7.5%
Polymenorrhea (%) 103 2.9% 92 0% 80 1.2%
Opsomenorrhea (%) 103 3.9% 92 3.3% 80 2.5%
Amenorrhea (%) 103 5.8% 92 10.9% 80 13.8%
Pregnancies 98 0.59 ±0.77
∧∧∧ 87 0.15 ±0.45 81 0.42 ± 0.78
Births 97 0.51 ±0.71
∧∧∧ 87 0.10 ±0.34
∗ 81 0.31 ± 0.63
Miscarriages 89 0.07 ±0.36 86 0.05 ±0.26 78 0.08 ± 0.35
Rate of infertility (%) 40 25.0%∧ 20 55.0% 28 50.0%
##P<0.01;###P<0.001 between group 1 and group 3.
∗P<0.05; ∗∗P<0.01; ∗∗∗P<0.001 between group 2 and group 3.
∧P<0.05; ∧∧P<0.01; ∧∧∧P<0.001 between group 1 and group 2.
n = number of patients.
120min (r = 0.438 and r = 0.428, P<0.05) only in
obese PCOS patients. Again, WSR correlates better with SBP,
DBP, and the rate of hypertension than WHR (r = 0.286,
r = 0.263, and r = 0.198, resp., versus r = 0.136, r = 0.135,
and r = 0.032, resp., P<0.05).
Diﬀerences in HDL-cholesterol, VLDL-cholesterol, and
triglycerides were found between the lean PCOS patients and
the other two groups. There is an intermediate correlation
between the body weight and the levels of triglycerides (r =
0.39, P<0.01) that after dividing the patients into groups
persistedonlyintheleanPCOSgroup.Onlyinthesepatients,
we observe a negative correlation between HDL-cholesterol
and body weight (r =− 0.45, P<0.01). The same
as for carbohydrate metabolism, WSR also shows stronger
correlation than WHR with the levels of HDL (r =− 0.27
versus r =− 0.10), VLDL-choleserol (r = 0.38 versus r =
0.29, P<0.05), and TG (r = 0.41 versus r = 0.27, P<0.05)
but not with TC (r = 0.03 versus r = 0.14).
As for liver function, the levels of the liver enzymes and
the rate of liver stetaosis are signiﬁcantly lower in the lean
PCOSpatients.Astrongcorrelationbetweenthebodyweight
and the presence of liver steatosis (r = 0.56, P<0.01) was
found so we can say that the main factor for development
of nonalcoholic fatty liver disease is the obesity. The levels
of GGT but not ASAT, ALAT, or AP correlate with IRI on 0
and 60min and HOMA index. The rate of liver steatosis also
shows good correlation with IRI during the OGTT, HOMA
index, glucose/insulin ratio, and diastolic blood pressure.6 Obstetrics and Gynecology International
Table 5: Comparison between the family history for chronic diseases between the three groups.
Group 1 Group 2 Group 3
Obese Lean PCOS Obese PCOS
nnn
Diabetes mellitus (%) 106 40.6%∧ 79 24.1%∗ 75 42.7%
Arterial hypertension (%) 106 38.7%∧∧ 79 19.0%∗ 75 37.3%
Dislipidema (%) 105 0.9% 79 0% 75 0%
Obesity (%) 106 28.3%∧∧∧ 79 1.3%∗∗∗ 75 25.3%
CHD (coronary heart disease) (%) 106 0.9% 79 1.3% 75 5.3%
Menstrual disturbances (%) 106 0.9% 79 3.8% 75 1.3%
PCOS (%) 106 0%∧∧∧ 79 12.7%∗ 74 2.7%
∗P<0.05; ∗∗P<0.01; ∗∗∗P<0.001 between group 2 and group 3.
∧P<0.05; ∧∧P<0.01; ∧∧∧P<0.001 between group 1 and group 2.
n = number of patients.
Table 6: Comparison between the data about clinical hyperandrogenism between the three groups.
Group 1 Group 2 Group 3
Obese Lean PCOS Obese PCOS
nnn
Clinical hyperandrogenism 60 53.3%∧∧ 83 77.1%∗∗∗ 72 86.1%
Hirsutism 60 51.7%∧ 82 72.0%∗∗∗ 72 84.7%
Increased hair growth on the upper lip 48 31.2%∧ 67 53.7%∗∗ 55 58.2%
Increased hair growth on the sideburns 46 23.9%∧ 67 47.8%∗∗ 55 58.2%
Increased hair growth on the beard 47 37.6% 67 50.7%∗∗∗ 55 70.9%#
Increased hair growth on the chest 47 10.6%∧∧ 67 34.3%∗∗ 54 37.0%
Increased hair growth on the abdomen 48 27.1%∧∧∧ 67 62.7%∗∗ 56 60.7%
Increased hair growth on the inner thighs 48 14.6%∧∧∧ 66 50.0%∗∗∗ 55 65.5%
Acne 50 4.0% 70 12.9% 62 1.6%
Androgenic alopecia 50 4.0% 73 6.8% 63 1.6%
Ferriman-Gallwey score 12 7.42 ±2.47 37 9.16 ±3.59 15 9.40 ±4.17
#P<0.05; between group 1 and group 3.
∗P<0.05; ∗∗P<0.01; ∗∗∗P<0.001 between group 2 and group 3.
∧P<0.05; ∧∧P<0.01; ∧∧∧P<0.001 between group 1 and group 2.
n = number of patients.
WBC showed correlation with baseline blood glucose
and HOMA index (r = 0.340 and 0.410; P<0.05) but
not with the results during OGTT. There is also intermediate
correlation between WBC and VLDL and TG-levels (r =
0.358 and 0.333, resp., P<0.01). On the other hand, ESR
also shows good correlation to HOMA index, BMI, WHR,
and WSR (r = 0.360; r = 0.441; r = 0.242; r = 0.397;
P<0.01) and not to any of the androgen levels.
The levels of testosterone and androstendione did not
show signiﬁcant correlation to the results of OGTT, lipid
levels, blood pressure, liver enzymes, or blood count in
the total group. Hemoglobin and hematocirte show a weak
positive correlation to the testosterone levels (r = 0.239 and
r = 0.199) but not to the levels of other androgens.
Interestingly, obese PCOS patients have signiﬁcantly
higher rate of family history for coronary heart disease com-
pared to the other two groups (Table 8). Lean PCOS patients
have higher rate of family history of PCOS than obese PCOS
patients. On the other hand, obese patients with or without
PCOShavehigherrateoffamilyhistoryfordiabetesmellitus,
hypertension, and obesity than lean patients.
As expected, the main reason for admittance of the obese
patients without PCOS is obesity per se while for the other
two groups the leading reason are menstrual disturbances
followed by hirsutism. However, menstrual disturbances as
a reason for admittance are signiﬁcantly more common in
lean PCOS patients than in obese PCOS patients.
The use of metformin is most frequent in the obese
PCOS group and does not signiﬁcantly diﬀer between the
other two groups (Table 7). That can be explained by the
more prominent insulin resistance in patients that have both
o b e s i t ya n dP C O S .I tm u s tb en o t e d ,h o w e v e r ,t h a tl e a n
PCOS patients start insulin sensitizing therapy as frequent
as obese women without the syndrome. There still remains
opened the question how is insulin resistance detected in
every single patient (Table 8).
Of 375 women in our study 155 had the full set of
data from the OGTT (blood glucose and IRI on 0, 60,Obstetrics and Gynecology International 7
Table 7: Comparison between the reasons for admittance and the type of treatment before and after the admittance between the three
groups.
Group 1 Group 2 Group 3
Obese Lean PCOS Obese PCOS
nnn
Hirsutism 125 4.0%∧∧∧ 92 42.4% 79 35.4%###
Menstrual disturbances 125 9.6%∧∧∧ 92 75.0%∗∗ 79 49.4%###
Infertility 125 4.0% 92 4.3% 79 8.9%
Obesity 125 72.0%∧∧∧ 92 4.3%∗∗∗ 79 49.4%##
Other 124 20.2%∧ 92 9.8% 79 7.6%#
Mean hospital stay (days) 125 8.42 ±5.47
∧ 94 6.51 ±4.37 82 7.89 ±4.78
COC before the admittance 125 4.8%∧∧∧ 92 46.7%∗∗∗ 78 34.6%
Metformin before the admittance 125 10.4% 92 7.6% 78 17.9%#
Combination of COC and metformin before
the admittance 125 0% 92 0%∗∗ 65 7.7%#
Surgical treatment before the admittance 125 0%∧∧ 92 6.5%∗∗ 78 7.7%
COC after the admittance 125 4.8%∧∧∧ 92 28.3%∗∗∗ 78 28.2%
Metformin after the admittance 125 48.8% 92 44.6%∗∗∗ 78 78.2%###
Combination of COC and metformin before
the admittance 125 1.6%∧∧∧ 92 8.7%∗∗∗ 78 19.2%#
Surgical treatment after the admittance 125 0% 92 0% 78 0%
#P<0.05; ##P<0.01;###P<0.001 between group 1 and group 3.
∗P<0.05; ∗∗P<0.01; ∗∗∗P<0.001 between group 2 and group 3.
∧P<0.05; ∧∧P<0.01; ∧∧∧P<0.001 between group 1 and group 2.
n = number of patients.
Table 8: Insulin resistance according to diﬀerent criteria in the
general group (n = 155).
Number % from the total
number
IFG/IGT 20 12.9%
Increased baseline insulin 62 40.0%
Elevation of IRI over 100mU/L on
the 60min of OGTT 62 40.0%
Elevation of IRI over 100mU/L on
the 120min of OGTT 28 18.1%
Elevation of IRI over 100mU/L on
the 60 and/or 120min of OGTT 66 42.6%
Elevation of IRI over 100mU/L on
the 60 and 120min of OGTT 24 15.5%
Elevation of IRI more than 5 times
over the baseline 108 69.7%
Decreased baseline glucose/insulin
ratio (<0.333mmol/L/mU/L) 71 45.8%
Increased HOMA-index (%) 93 60.0%
and 120min). In every one of them, we assessed the presence
or the lack of impaired fasting glucose, glucose tolerance, or
insulin resistance according to these criteria.
The presence of insulin resistance using the increased
baseline insulin or insulin elevation over 100mU/L during
the OGTT correlates better with the arterial blood pressure
and lipid levels than when using elevation of IRI more than
5 times over the baseline (Table 9).
These data show a lower level of insulin resistance in
lean PCOS subjects compared to the other groups. There is
also a diﬀerent rate of insulin resistance when using diﬀerent
criteria in the total group and in every subgroup. In the three
groups, there is a higher rate of insulin resistance when using
the elevation of IRI more than 5 times over the baseline. In
this case, the rate of insulin resistance in the three groups
is similar. It should be noted, however, that the highest
elevation of IRI is seen in some patients on the 60min of
OGTTandinotherson120minoftheOGTT.Forthisreason
to beneﬁt from the full diagnostic power of the method, it is
necessary to measure IRI both on 60 and 120min, otherwise,
we would miss patients with insulin resistance.
4. Discussion
The aim of the study was to investigate some cardiovascular
risk factors in young women with PCOS. This is the largest
study on PCOS patients in Bulgaria.
The link between the obesity and reproductive problems
in women has been studied for a long time and is conﬁrmed
from the results of a number of epidemiological and clinical
studies (for review [26] ) .T h er a t eo fo b e s i t yi np a t i e n t s
with PCOS is between 30% and 70% depending on the
ethnicityandtheusedcriteriafordiagnosisofPCOS[27,28].
Therefore, PCOS patients can be divided into two main
phenotypes according to their BMI-lean and obese that
have very diﬀerent metabolic and cardiovascular risk proﬁle.
Although the insulin resistance is thought to be fundamental8 Obstetrics and Gynecology International
Table 9: Insulin resistance according to diﬀerent criteria.
Group 1 Group 2 Group 3
Obese Lean PCOS Obese PCOS
(n = 56) (n = 56) (n = 43)
nnn
IFG/IGT 6 10.7% 5 8.9% 9 20.9%
Increased baseline insulin 28 50.0% 5 8.9% 29 67.4%
Elevation of IRI over 100mU/L on the
60min of OGTT 26 46.4% 9 16.1% 27 62.8%
Elevation of IRI over 100mU/L on the
120min of OGTT 12 21.4% 5 8.9% 11 25.5%
Elevation of IRI over 100mU/L on the 60
and/or 120min of OGTT 29 51.8% 10 17.9% 27 62.8%
Elevation of IRI over 100mU/L on the 60
and 120min of OGTT 9 16.1% 4 7.1% 11 25.6%
Elevation of IRI more than 5 times over the
baseline (%) 39 69.6% 40 71.4% 29 67.4%
Decreased baseline glucose/insulin ratio
(< 0.333mmol/L/mU/L) 30 53.6% 12 21.4% 29 67.4%
Increased HOMA-index 39 69.6% 17 30.4% 37 86.0%
for PCOS, obesity tends to worsen it and the metabolic
disturbances [29]. Our data support this theory and show
that the indices of carbohydrate metabolism—fasting blood
glucose and blood glucose on 60min of OGTT and IRI on
0, 60, and 120min of OGTT and HOMA index are sig-
niﬁcantly lower in lean PCOS subjects but do not diﬀer
signiﬁcantly in obese and obese PCOS women although
obese PCOS patients have higher mean values. This is why
it can be postulated that the obesity and PCOS worsen their
unwanted eﬀects on the carbohydrate metabolism and lean
PCOS women have comparatively discrete disturbances.
Our data show that the metabolic indices, SBP, DBP, and
hematological results are highly dependent on the presence
of obesity and not on the presence of PCOS in the patients.
The hyperinsulinemia has an important role in the devel-
opment of hypertension by increasing the sodium retention
[30], and in this way, it leads to increased intracellular lev-
els of sodium and calcium [31]. Insulin also increases the
release of IGF-1, which can lead to hypertension as a result
of nonstriated-muscle hypertrophy. We found a correlation
between IRI during OGTT and systolic and diastolic blood
pressure.
Many patients with PCOS have classical signs of meta-
bolic syndrome. In healthy women with normal body weight
and preserved insulin sensitivity, the adipocytes release small
amounts of free fatty acids (FFAs) and have a normal
activity of the lipoprotein lipase (LPL). In these women,
the physiological levels of testosterone act in synchrony with
the insulin and suppress the release of FFA, so they have
antilipolytic eﬀect [32]. In women with obesity, there is
an increased production of FFA and decreased activity of
LPL as a result of the prominent insulin resistance. In these
conditions, the high androgen levels additionally worsen
the disturbances in the lipid metabolism [32]. It is thought
that approximately 70% of the patients with PCOS have
disturbances in serum lipid levels [33]. Even after weight
adjustment, the lipid abnormalities persist [10, 34]. In our
study, we found diﬀerences in HDL, VLDL, and TG between
the lean PCOS patients and the other two groups.
There are data that the total white blood cell count
is an independent risk factor for coronary heart disease
[35, 36] and related to it morbidity and mortality [37]. In
some studies in women with PCOS, there are higher WBC
levels than in healthy women that correlate well with the
markers of insulin resistance (HOMA index) [38]. We also
found correlation between WBC and VLDL and TG-levels
that promote the development of atherosclerosis. We found
signiﬁcantly higher levels of ESR in obese compared to lean
PCOS patients. ESR showed positive correlation to BMI,
WHR, WSR, and HOMA index. To our knowledge, this is
the ﬁrst study that assesses the ESR in PCOS patients. The
increased levels of white blood cells and ESR are probably
linked to subclinical inﬂammation that plays an important
role in early clinical manifestation of atherosclerosis.
Testosterone stimulates the hematopoiesis in the bone
marrow and, consequently, increases the hematocrit [39].
Hypogonadal men have a statistically signiﬁcant lower he-
matocrit [40]. In accordance to this, we found a weak cor-
relation between the levels of testosterone but not with
other androgens to hemoglobin and hematocrit levels. In
our study, lean and obese PCOS patients do not signiﬁcantly
diﬀer in their testosterone levels and that is why they have
similar blood count indices. On the other hand, obese PCOS
patients have higher testosterone than obese women without
PCOS and that goes with signiﬁcantly higher hemoglobin
but not hematocrit. It is important to note that hemoglobin
andhematocritcorrelatewithtestosteronebutnotwithother
androgen levels.
The indices of clinical hyperandrogenism are the highest
in the obese PCOS patients and this conﬁrms the theoryObstetrics and Gynecology International 9
that obesity worsens the disturbances caused by PCOS and
aggravates the clinical presentation of the syndrome.
The family history for obesity is more frequent in obese
patients no mater if they have PCOS or not. On the other
hand, the family history for PCOS is more frequent in lean
PCOS women and this suggests the more important role of
the genetic milieu in these cases. Unlike that for obese PCOS
women, probably of utmost importance is the presence of
obesity. Studies show higher prevalence of diabetes mellitus
in relatives of PCOS patients [41, 42] and particularly of
those with impaired glucose tolerance or overt diabetes [43].
We found a higher rate of family history for diabetes only in
obesePCOSpatients.Thesepatientsalsohavenotablyhigher
family history of coronary heart disease that can be related to
the increased cardiovascular risk in later life.
T h ea b s o l u t ew a i s tc i r c u m f e r e n c e( >88cm) and the
WHR (>0.85) are both used as measures of central obesity
in women [44]. Recently, another measure of central obe-
sity was proposed which has shown superiority to BMI
in predicting cardiovascular disease risk is the waist-to-
stature ratio (WSR), where a ratio of ≥0.5 (i.e., a waist
circumference at least half of the individual’s height) is
predictive of increased risk [45]. In light of concerns raised
about the ability of BMI alone to predict cardiovascular risk,
some studies have recently attempted to compare BMI with
waist circumference and other anthropometric measures
of obesity, such as WHR and WSR, as predictors for car-
diovascular risk. In a meta-analysis of abdominal obesity
indices comparing BMI, waist circumference, WHR, and
WSR, researchers concluded that WSR was the best predictor
for both hypertension and dislipidemia for both men and
women, while BMI was the least accurate predictor of hyper-
tension [46]. To our knowledge, our study is the ﬁrst to
show that WSR is a better marker for unfavorable metabolic
proﬁle (OGTT results, blood pressure, and lipid proﬁle)
than WHR in a speciﬁc group of PCOS patients. Further
large-scale studies are necessary to position the diﬀerent
anthropometric parameters, according to deﬁnite endpoints.
Our results conﬁrm the presence of insulin resistance
both in lean and obese PCOS women that is, however, more
pronounced in obese subjects. According to our data, the
increased baseline insulin is much more sensitive in patients
with obesity with or without PCOS than the standard
OGTTwithoutIRImeasurementregardingthecarbohydrate
metabolism disturbances. This is not seen in lean PCOS
subjects where the rate of IFG/IGT is the same as that of
increased baseline insulin. In our previous study, it was
shown that IGT and/or diabetes on 120min of OGTT was
diagnosed in 8.5% of the women with PCOS while IFG
and/or diabetes on 0min of OGGT—only in 2.2% of the
patients [47]. In the present study, however, patients with
diabetes were excluded, but in the whole population with
OGTT, 12.9% had disglycemia—IFG and/or IGT.
In the three groups, insulin resistance according to the
criteria of IRI over 100mU/L during the OGTT is seen two
times more frequently on 60min than on 120min. So, if
for some reason only two measurements of IRI during the
OGTT are available, they must be on 0 and 60min and not
on 0 and 120min. This is mostly true for lean PCOS patients
because in the other two groups the diagnostic powers of
the increased baseline insulin levels are comparable to the
response of the insulin on 60min and exceed that on the
120min.
As to the HOMA index, its ability to diagnose the in-
sulin resistance is highest in obese PCOS patients and lowest
in lean PCOS patients. That is true also for decreased glu-
cose/insulin ratio.
Limitations. Ourstudyhasallthelimitationsofretrospective
crossectional studies—lack of all data for each patient, dif-
ferent clinical approach during the diﬀerent periods, and so
forth.
5. Conclusion
(1) Obesity is the most important factor for unfavorable
metabolic and cardiovascular risk proﬁle in PCOS
patients.
(2) In our study population, WSR is a better anthropo-
metric marker of adverse metabolic proﬁle in women
with PCOS and/or obesity than WHR.
(3) Carbohydrate metabolism testing is necessary in all
PCOS patients because of the high prevalence of its
disturbances.
(4) In patients with obesity with or without PCOS only
the baseline indices-glucose and IRI and HOMA
index can be used.
(5) In lean PCOS patients, an OGTT with IRI measure-
ment on 0, 60, and 120min is highly recommended.
(6) ESRshowpositivecorrelationwithBMIandtheindi-
cesofinsulinresistance,butnotwithandrogenlevels.
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